Stepping Into a New Era: Sotatercept for the Treatment of Combined Precapillary and Postcapillary Pulmonary Hypertension From Heart Failure With Preserved Ejection Fraction

This publication has 15 references indexed in Scilit:

• Sotatercept in Pulmonary Arterial Hypertension
  JACC, 2026
• Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death
  New England Journal of Medicine, 2025
• Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study
  Circulation, 2024
• Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
  New England Journal of Medicine, 2023
• Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
  European Journal of Heart Failure, 2022
• Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure
  Circulation, 2021
• Sotatercept for the Treatment of Pulmonary Arterial Hypertension
  New England Journal of Medicine, 2021
• Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study
  The Lancet Respiratory Medicine, 2020
• Exercise Intolerance in Heart Failure With Preserved Ejection Fraction
  Circulation, 2018
• Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial
  European Heart Journal, 2017